Quintiles Appoints Oren Cohen to Senior Vice President, Clinical Research Strategies
Oren Cohen, MD, promoted to Quintiles' senior vice president of clinical research strategies
Research Triangle Park, NC-April 16, 2008-Quintiles Transnational (www.quintiles.com) today announced the appointment of Oren Cohen, MD, as senior vice president, clinical research strategies.
Most recently, Cohen held the position of chief medical and scientific officer. In his new role, Cohen will be responsible for evaluating and implementing new clinical research strategies, part of the company's "shape the future" objective. He also will continue to serve as managing director of Quintiles public health and government services.
Cohen is also a consulting professor of medicine at Duke University School of Medicine. He earned a medical degree from Duke University and completed his residency at New York Hospital/Cornell University Medical Center and his fellowship in infectious diseases at the National Institutes of Health. He is board-certified in internal medicine and infectious diseases and has written more than 50 scientific articles and book chapters. He is a fellow of the Infectious Diseases Society of America and serves as a reviewer for several highly respected medical journals. He has won numerous awards for his professional achievements and has presented his work at dozens of conferences around the world.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
